Clinical Trials
36
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (27 trials with phase data)• Click on a phase to view related trials
A Study Evaluating MM-310 in Patients With Solid Tumors
- Conditions
- Solid TumorsOvarian CancerTriple Negative Breast CancerSoft Tissue SarcomaUrothelial CarcinomaGastric CarcinomaSquamous Cell Carcinoma of the Head and NeckEndometrial CarcinomaPancreatic Ductal AdenocarcinomaNon-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2017-03-10
- Last Posted Date
- 2018-02-27
- Lead Sponsor
- Merrimack Pharmaceuticals
- Target Recruit Count
- 34
- Registration Number
- NCT03076372
- Locations
- 🇺🇸
Honor Health, Scottsdale, Arizona, United States
🇺🇸University California San Francisco, San Francisco, California, United States
🇺🇸Mayo Clinic, Rochester, Minnesota, United States
Evaluation of MM-151 + Nal-IRI + 5-FU + Leucovorin in RAS/RAF Wild-type Metastatic Colorectal Cancer
- Conditions
- Colorectal Cancer
- Interventions
- First Posted Date
- 2016-05-27
- Last Posted Date
- 2017-01-11
- Lead Sponsor
- Merrimack Pharmaceuticals
- Registration Number
- NCT02785068
Phase 1 Combination Study of MM-151 With MM-121, MM-141, or Trametinib
- Conditions
- Colorectal CancerNon-small Cell Lung CancerSquamous Cell Carcinoma of the Head and Neck
- Interventions
- First Posted Date
- 2015-09-02
- Last Posted Date
- 2017-09-05
- Lead Sponsor
- Merrimack Pharmaceuticals
- Target Recruit Count
- 5
- Registration Number
- NCT02538627
- Locations
- 🇺🇸
University of Colorado, Aurora, Colorado, United States
🇺🇸Northside Hospital, Sandy Springs, Georgia, United States
🇺🇸Northwestern, Chicago, Illinois, United States
A Phase 2 Study of MM-141 Plus Nab-paclitaxel and Gemcitabine in Front-line Metastatic Pancreatic Cancer
- Conditions
- Pancreatic Cancer
- Interventions
- First Posted Date
- 2015-03-26
- Last Posted Date
- 2018-09-18
- Lead Sponsor
- Merrimack Pharmaceuticals
- Target Recruit Count
- 88
- Registration Number
- NCT02399137
- Locations
- 🇺🇸
Banner MD Anderson Cancer Ctr., Gilbert, Arizona, United States
🇺🇸Pacific Cancer Medical Center, Inc., Anaheim, California, United States
🇺🇸St. Jude Heritage Healthcare, Fullerton, California, United States
MM-302 Plus Trastuzumab vs. Chemotherapy of Physician's Choice Plus Trastuzumab in HER2-Positive Locally Advanced/Metastatic Breast Cancer Patients
- Conditions
- Breast CancerHER2 Positive Breast Cancer
- Interventions
- First Posted Date
- 2014-08-11
- Last Posted Date
- 2017-01-06
- Lead Sponsor
- Merrimack Pharmaceuticals
- Target Recruit Count
- 113
- Registration Number
- NCT02213744
- Locations
- 🇺🇸
Palo Verde Cancer Center, Glendale, Arizona, United States
🇺🇸Mayo Clinic Cancer Center, Rochester, Minnesota, United States
🇺🇸University of Arizona Cancer Center, Tucson, Arizona, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- Next
News
Merrimack Pharmaceuticals Advances Oncology Pipeline with MM-398 and MM-121
Merrimack Pharmaceuticals is focusing on advancing its oncology pipeline, particularly MM-398 for metastatic pancreatic cancer and MM-121 for various solid tumors.